Skip to main content

TGBA01AD









TGBA01AD


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search
























TGBA01AD
Clinical data
Synonyms FKB01MD
Routes of
administration		 By mouth

Pharmacokinetic data
Bioavailability 17%[1]
Elimination half-life
 4 hours[1]

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]



See also[edit]


  • List of investigational antidepressants


References[edit]





  1. ^ abc Fabre-Kramer: FKB01MD


  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  3. ^ "TGBA01AD". AdisInsight.















Retrieved from "https://en.wikipedia.org/w/index.php?title=TGBA01AD&oldid=869997700"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.828","walltime":"1.007","ppvisitednodes":{"value":3989,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":312158,"limit":2097152},"templateargumentsize":{"value":1702,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":6312,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 599.670 1 -total"," 59.27% 355.409 1 Template:Drugbox"," 39.87% 239.085 1 Template:Infobox"," 25.71% 154.201 21 Template:Navbox"," 22.23% 133.309 1 Template:Reflist"," 18.26% 109.502 1 Template:Cite_journal"," 12.43% 74.525 16 Template:Unbulleted_list"," 9.09% 54.520 1 Template:Serotonin_receptor_modulators"," 6.31% 37.815 1 Template:Monoamine_reuptake_inhibitors"," 5.11% 30.641 1 Template:Infobox_drug/chemical_formula"]},"scribunto":{"limitreport-timeusage":{"value":"0.240","limit":"10.000"},"limitreport-memusage":{"value":4727693,"limit":52428800}},"cachereport":{"origin":"mw1244","timestamp":"20181220182308","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":99,"wgHostname":"mw1264"});});
-